Similar articles

• Acoramidis in Transthyretin Amyloid Cardiomyopathy.

  Verbeeck J, De Backer M, Buyse M. Verbeeck J, et al. N Engl J Med. 2024 Apr 11;390(14):1345-1346. doi: 10.1056/NEJMc2401669. N Engl J Med. 2024. PMID: 38598811 No abstract available.
• Acoramidis in Transthyretin Amyloid Cardiomyopathy. Reply.

  Gillmore JD, Lystig T, Fox JC. Gillmore JD, et al. N Engl J Med. 2024 Apr 11;390(14):1346-1347. doi: 10.1056/NEJMc2401669. N Engl J Med. 2024. PMID: 38598813 No abstract available.
• Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.

  Capovilla TM, Lalario A, Rossi M, Porcari A, Aimo A, Limongelli G, Emdin M, Merlo M, Sinagra G. Capovilla TM, et al. Heart Fail Clin. 2024 Jul;20(3):333-341. doi: 10.1016/j.hfc.2024.03.007. Epub 2024 Apr 12. Heart Fail Clin. 2024. PMID: 38844304 Review.
• Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.

  Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, García-Pavía P, Grodin JL, Grogan M, Hanna M, Masri A, Nativi-Nicolau J, Obici L, Hvitfeldt Poulsen S, Sarswat N, Shah K, Soman P, Lystig T, Cao X, Wang K, Pecoraro ML, Tamby JF, Katz L, Sinha U, Fox JC, Maurer MS. Judge DP, et al. Circulation. 2025 Mar 4;151(9):601-611. doi: 10.1161/CIRCULATIONAHA.124.072771. Epub 2024 Nov 18. Circulation. 2025. PMID: 39556242 Free PMC article. Clinical Trial.
• Acoramidis: First Approval.

  Lee A. Lee A. Drugs. 2025 Jun;85(6):833-837. doi: 10.1007/s40265-025-02159-z. Epub 2025 Apr 4. Drugs. 2025. PMID: 40180779 Review.